119 related articles for article (PubMed ID: 36739175)
1. Intermediate-dose cyclophosphamide and bortezomib for PBSC mobilization in multiple myeloma.
Sawazaki A; Sugimori C; Yamaguchi M; Nakao S
Transfus Apher Sci; 2023 Jun; 62(3):103649. PubMed ID: 36739175
[TBL] [Abstract][Full Text] [Related]
2. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715
[TBL] [Abstract][Full Text] [Related]
3. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma.
Hiwase DK; Bollard G; Hiwase S; Bailey M; Muirhead J; Schwarer AP
Cytotherapy; 2007; 9(6):539-47. PubMed ID: 17882718
[TBL] [Abstract][Full Text] [Related]
4. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.
Laszlo D; Marcacci GP; Martino M; Radice D; Rabascio C; Lucchetti B; Magarò A; Caime A; Menna S; Lionetti MT; Bertolini F
Transfus Apher Sci; 2020 Oct; 59(5):102819. PubMed ID: 32499108
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
[TBL] [Abstract][Full Text] [Related]
6. Peripheral blood stem cell mobilisation following bortezomib, lenalidomide and dexamethasone induction for multiple myeloma: a real-world single-centre experience.
Sim S; Quach H; Pham T; Smooker V; Filshie R
Intern Med J; 2024 Jan; 54(1):108-114. PubMed ID: 37357752
[TBL] [Abstract][Full Text] [Related]
7. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.
Awan F; Kochuparambil ST; Falconer DE; Cumpston A; Leadmon S; Watkins K; Deremer D; Jillella A; Craig M; Hamadani M
Bone Marrow Transplant; 2013 Oct; 48(10):1279-84. PubMed ID: 23584435
[TBL] [Abstract][Full Text] [Related]
8. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.
Demirer T; Buckner CD; Gooley T; Appelbaum FR; Rowley S; Chauncey T; Lilleby K; Storb R; Bensinger WI
Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M
J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.
Shimura Y; Kuroda J; Uchiyama H; Kawata-Iida E; Tsutsumi Y; Nagoshi H; Mizutani S; Yamamoto-Sugitani M; Matsumoto Y; Kobayashi T; Horiike S; Shimazaki C; Kaneko H; Kobayashi Y; Taniwaki M
J Clin Apher; 2013 Oct; 28(5):368-73. PubMed ID: 23804501
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma.
Figueiredo A; Atkins H; Mallick R; Kekre N; Kew A; McCurdy A
Curr Oncol; 2020 Apr; 27(2):e81-e85. PubMed ID: 32489256
[TBL] [Abstract][Full Text] [Related]
12. Higher efficacy of intermediate dose cytarabine + G-CSF compared to cyclophosphamide + G-CSF in hematopoietic stem cell mobilization in patients with multiple myeloma.
Bogucka-Fedorczuk A; Czyz A; Kalicińska E; Sawicki M; Laszkowska-Lewko M; Wicherska-Pawłowska K; Rybka J; Szeremet A; Prajs I; Szymczak D; Wróbel T
J Clin Apher; 2020 Aug; 35(4):246-254. PubMed ID: 32298020
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of two doses of cyclophosphamide with etoposide and G-CSF for mobilization of peripheral blood stem cells in 318 patients with stage II-III breast cancer.
Schwartzberg LS; Weaver CH; Birch R; Manner C; Tauer K; Beeker T; Morgan-Ihrig C; MacAneny B; Leff R; Smith R; Hainsworth J; Greco T; Schwerkoske J; Murphy MN; Buckner CD
J Hematother; 1998 Apr; 7(2):141-50. PubMed ID: 9597571
[TBL] [Abstract][Full Text] [Related]
14. Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study.
Zannetti BA; Saraceni F; Cellini C; Fabbri E; Monaco F; Guarini A; Laszlo D; Martino M; Olivieri A; Imola M; Tosi P; Chiarucci M; Zuffa E; Lanza F
Transplant Cell Ther; 2021 Mar; 27(3):244.e1-244.e8. PubMed ID: 33781522
[TBL] [Abstract][Full Text] [Related]
15. Low-dose cyclophosphamide and granulocyte colony-stimulating factor are sufficient for peripheral blood stem cell mobilization in patients with multiple myeloma.
Keklik M; Karakus E; Kaynar L; Akyol G; Guven ZT; Celik S; Baydar M; Sanlı N; Unal A; Cetin M
Transfus Apher Sci; 2020 Oct; 59(5):102844. PubMed ID: 32586769
[TBL] [Abstract][Full Text] [Related]
16. Addition of bortezomib to high-dose cyclophosphamide therapy as a conditioning regimen for autologous peripheral blood stem cell harvest leads to an increased yield of hematopoietic stem cells.
Ohno S; Hayashi K; Shimizu R; Ishii A; Tanaka H
J Clin Exp Hematop; 2022 Sep; 62(3):147-153. PubMed ID: 35979578
[TBL] [Abstract][Full Text] [Related]
17. Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone.
Benyamini N; Avivi I; Dann EJ; Zuckerman T; Lavi N; Katz T
Ann Hematol; 2017 Mar; 96(3):461-467. PubMed ID: 28013359
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma.
Chua CC; Lim HY; Chai KL; Ong J; Sim S; Wood C; Dickinson M; Campbell P; Hempton J; King H; Dowsing C; Bergin K; Muir S; Gibbs S; Grigg A
Bone Marrow Transplant; 2018 Sep; 53(9):1116-1123. PubMed ID: 29523889
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Tuchman SA; Bacon WA; Huang LW; Long G; Rizzieri D; Horwitz M; Chute JP; Sullivan K; Morris Engemann A; Yopp A; Li Z; Corbet K; Chao N; Gasparetto C
J Clin Apher; 2015 Jun; 30(3):176-82. PubMed ID: 25293363
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients.
Winkelmann N; Desole M; Hilgendorf I; Ernst T; Sayer HG; Kunert C; Mügge LO; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2016 Dec; 142(12):2603-2610. PubMed ID: 27640002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
